Aodong
敖东
Founded in 1957, Jilin Aodong Pharmaceutical Group Co., Ltd. is a holding conglomerate that integrates the pharmaceutical and financial industries. The company’s product range includes series such as Anshen Bunao Oral Liquid, Xuefu Zhuyu Oral Liquid, Linaoxin Capsules, Xinnao Shutong Capsules, and more.
The predecessor of Jilin Aodong Pharmaceutical Group was the Yanchang Luchang, established in 1957, and then transformed into Aodong Pharmaceutical Factory in 1981. In March 1993, it was restructured and became Jilin Aodong Pharmaceutical Group Co., Ltd. The company went public on the Shenzhen Stock Exchange on October 28, 1996. Presently, the company controls 5 specialized pharmaceutical subsidiaries engaged in modern traditional Chinese medicine, biochemical drugs, and plant chemistry drugs. It also has 9 pharmaceutical sales subsidiaries, 8 pharmaceutical supporting subsidiaries, 2 high-end health product companies, 1 highway toll company, and 1 international subsidiary in Hong Kong. It has established an industrial chain operation mode of “Company + Standardized Base + Licensed Farmers,” owning planting and breeding bases. Gradually, the company has evolved into a large-scale modern pharmaceutical enterprise with pharmaceuticals as the foundation, driven by a dual-wheel “Industry + Finance” development model.
The company’s products include “Anshen Bunao Liquid,” “Injection Nucleic Acid II,” “Small Ox Spleen Extract Injection,” “Xuefu Zhuyu Oral Liquid,” “Naoxin Shutong Oral Liquid,” “Pediatric Chaigui Fever-Reducing Oral Liquid,” “Yangxue Drink Oral Liquid,” “Xinnao Shutong Capsules,” “Lingbei Cough Syrup,” “Linaoxin Capsules,” “Shaofu Zhuyu Granules,” “Shen Fukang Tablets,” “Lai Aminopyrine,” “Compound Dichloroacetic Acid Isopropanol Injection,” “Yunkang Granules,” “Gen Tongping Pills,” “Shenjin Tablets,” “Aotaile Capsules,” “Lutai Granules,” “Injection Adenosine Monophosphate,” “Pediatric Ammonium Chloride Paracetamol and Pheniramine Maleate Granules,” and “Stroke Rebuilding Pills.” These products have earned consistent market praise for their stable quality and notable efficacy, driving the company’s continuous development and growth in the pharmaceutical sector.
Guided by the core values of “Focusing on People, Specializing in Medicine,” the company adheres to the development strategy of “Large Variety Group, Multiple Variety Groups” in the pharmaceutical industry. It follows the dual-wheel “Industry + Finance” development path, aligns with industry trends, leverages its advantages, and solidifies its steady development. The company is committed to fulfilling its corporate mission of “Providing Safe, Reliable, and Trustworthy Medicines for Society.”